Nov 03, 2017

Six MCDI Abstracts on Malaria Vaccine Trials to be presented at ASTMH Conference

At this year's American Society for Tropical Medicine and Hygiene (ASTMH) Annual Meeting, team members of the Equatoguinean Malaria Vaccine Initiative (EGMVI) will be presenting on their findings from the first clinical trial of Sanaria Inc.'s whole-sporozoite plasmodium falciparum malaria vaccine candidate (PfSPZ) in Equatorial Guinea. MCDI manages the initiative in partnership with Sanaria, Ifakara Health Institute (IHI), Swiss Tropical Public Health Institute (Swiss TPH) and the Ministry of Health and Social welfare of Equatorial Guinea. The initiative is funded by the Government of Equatorial Guinea, Marathon Oil, Noble Energy and Atlantic Methanol (AMPCO). The presentation will explore the effects of the first trial as well as the role of community engagement during the trial.

EGMVI Co-Investigator Dr. Vicente Urbano will present three separate abstracts about the clinical trials. "Safety, tolerability, immunogenicity and efficacy of PfSPZ vaccine versus PfSPZ-CVac in Equatoguinean Young Adults" and "Safety, tolerability and immunogenicity of PfSPZ vaccine in Equatoguinean children and older adults" both will provide valuable information on whether the PfSPZ vaccine or the PfSPZ-CVac (PfSPZ with chloroquine prophylaxis) could be used in a mass vaccination program aimed at regional elimination of malaria. Urbano will also present "Exceptional tolerability of chloroquine when administered as chemoprophylaxis with aseptic, live, cryopreserved non-attenuated whole Plasmodium falciparum sporozoites (PfSPZ-CVac) in healthy Equatoguinean young adults", which details the surprising tolerability to chloroquine during the PfSPZ-CVac trial, as there were questions prior to the study about the possible adverse side effects of its use.

EGMVI Medical Officer Dr. Beltran Ekua Ntutumu Pasialo will present his abstract "Asymptomatic Loa loa infection in Equatoguinean adult subjects in a whole sporozoite malaria vaccine trial: what is a researcher to do?" which will detail the presence of the Loa loa filarial nematode in five of the individuals who were originally selected for the vaccine trial. The presentation will discuss the rationale for treating incidental, asymptomatic loiasis discovered during an unrelated clinical trial.

Jose Raso, Manager of the EGMVI Lab, will present "Prevalence of intestinal helminth infection in Equatoguinean infants, children, adolescents and adults and its impact on immunogenicity to a live, attenuated, whole sporozoite malaria vaccine". This study examines the prevalence of two species of helminths in the Equatoguinean population, as this data was collected as an exclusionary criteria for participation in EGMVI’s vaccine trial. This presentation will also assess the potential impact of recent soil-transmitted helminth infections on PfSPZ vaccine immunogenicity.

"The Role of community engagement in the success of the first clinical malaria vaccine trials in Equatorial Guinea" will be presented by Esther Eburi, Vaccine Project Officer. The PfSPZ vaccine trials are the first clinical trials to ever occur in Equatorial Guinea, which resulted in some difficulties in gaining the support of the public to volunteer or to support the project. Eburi's presentation will outline the methods used to garner public support for the vaccine trials that has resulted in recruiting 135 volunteers, including infants, to the second phase trial.

To follow along with MCDI's presence at this year's ASTMH Annual Meeting, follow MCDI on twitter @MCDITweets.

Back to News & Events